Experiences with

Estramustine

Long responders to estramustine monophosphate. Report of two cases and literature review. https://www.ncbi.nlm.nih.gov/pubmed/31475684

GETUG-12 (Groupe d’Étude des Tumeurs Urogénitales)19 randomly assigned 413 patients with high-risk clinically localized disease treated with local therapy to AS (36 months) plus four cycles of adjuvant CT with docetaxel and estramustine or AS alone.

This is my story: [u]Diagnosis [/u] Date: November 2002 Age at diagnosis: 37 Age now: 53 [u]Treatment [/u] 1.Chemotherapy - Paclitaxel, Carboplatin, Estramustine - for 6 months 2.Intensity Modulated Radiotherapy - 81gy over three months 3.Zolodex - with a break in 2009 4.Zometa -

rapid cytotoxic T-lymphocyte activation without the costs and cell availability limitations of cell-based approaches.[50] The first randomized phase II trial of PPVs in prostate cancer, reported in 2010, was an open-label, multicenter, crossover study comparing a four-peptide vaccine plus a low dose of estramustine

Chemo would be Ketoconazole and Doxorubicin for weeks 1, 3, and 5 and Estramustine and Docetaxel for weeks 2, 4, and 6. No treatments during weeks 7 and 8. Not sure if radiotherapy is included or not. There is my conundrum. I'm at a fork in the road and I don't know which way to go.

"Twenty-four (59%) patients had previously undergone chemotherapy, while 11 (27%) received docetaxel, and 24 (59%) estramustine." "The prostatic-specific antigen (PSA) level declined in 17 (41%) patients from the baseline value, following dutasteride treatment.

In weeks 2, 4, and 6, treatment consisted of paclitaxel 100 mg/m2 intravenously on the first day of every week in combination with estramustine 280 mg orally 3 times a day for 7 days. 30 mg of Prednisone everyday through the three courses of chemotherapy. Last aside.

It was the aim of this study to assess the activity of estramustine and colchicine, two microtubule inhibitors, in hormone-refractory prostate cancer.

Other trials, not considered because retinoic acid was not used as monotherapy: [B2c] (1999 - US - Phase I) 13-cis-retinoic acid, interferon alfa, and paclitaxel [B2d] (2003 - US - Phase I) 13- cis-retinoic acid, paclitaxel and interferon alpha [B2e] (2010 US - Phase II) mitoxantrone, estramustine